Education
About Us
Working with TipRanks
Follow Us
Camurus AB (SE:CAMX)
:CAMX
CAMX Stock Chart & Stats
kr665.50
-kr17.00(-2.71%)
At close: 4:00 PM EST
kr665.50
-kr17.00(-2.71%)
Day’s Range― - ―
52-Week Rangekr483.80 - kr754.50
Previous CloseN/A
Volume19.01K
Average Volume (3M)108.56K
Market Cap
kr38.51B
Enterprise Valuekr37.66B
Total Cash (Recent Filing)kr3.35B
Total Debt (Recent Filing)kr103.80M
Price to Earnings (P/E)48.7
Beta0.79
Next Earnings
Feb 12, 2026EPS Estimate
2.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.27
Shares Outstanding59,848,633
10 Day Avg. Volume188,941
30 Day Avg. Volume108,561
Financial Highlights & Ratios
PEG Ratio-15.28
Price to Book (P/B)9.97
Price to Sales (P/S)17.56
P/FCF Ratio91.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Camurus AB News
CAMX FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was kr483.80 and its highest was kr754.50 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is kr38.51B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is Feb 12, 2026 which is in 86 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on Nov 06, 2025. The company reported kr3.27 earnings per share for the quarter, missing the consensus estimate of kr3.298 by -kr0.028.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Overvalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 2.04.
How many shares outstanding does Camurus AB have?
Camurus AB has 59,848,633 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of kr3.27 in its last earnings report, missing expectations of kr3.298. Following the earnings report the stock price went down -5.862%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in SE:CAMX
Company Description
Camurus AB
Camurus AB (CAMX) is a Swedish pharmaceutical company specializing in the development and commercialization of innovative medicines for patients with complex diseases. The company focuses primarily on long-acting drug delivery systems and is active in therapeutic areas such as pain management, addiction treatment, and oncology. Camurus's core products include its proprietary formulations that utilize the company's FluidCrystal® technology, enabling sustained release of active substances and improving patient adherence to treatment regimens.
CAMX Company Deck
CAMX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook with both significant achievements and notable challenges. Camurus showed strong revenue growth, profitability, and positive R&D developments, but faced hurdles with lowered revenue guidance, slowed Buvidal sales, and funding issues in the U.K. market.View all SE:CAMX earnings summariesTechnical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
BioArctic AB Class B
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Options Prices
Currently, No data available
---